DJIA 17,730.11 -27.80 -0.16%
NASDAQ 5,009.21 0.00 0.00%
S&P 500 2,076.78 -0.64 -0.03%
market minute promo

Targacept , Inc. (NASDAQ: TRGT)

2.77 0.01 (0.36%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TRGT $2.77 0.36%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.84
Previous Close $2.76
Daily Range $2.75 - $2.84
52-Week Range $2.15 - $4.68
Market Cap $93.8M
P/E Ratio -3.79
Dividend (Yield) $0.00 (0.0%)
Volume 131,060
Average Daily Volume 101,184
Current FY EPS -$0.89

Sector

Healthcare

Industry

Drug Makers

Targacept , Inc. (TRGT) Description

A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Website: http://www.targacept.com/

News & Commentary

Keep an Eye on Biogen, Johnson & Johnson, and Merck Today

Biogen, Johnson & Johnson, and Merck could all make health care headlines this morning. Here’s all the news you need to know.

Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation

Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation Coagulation Factor VIIa in Patients With Hemophilia A or B and Preclinical Results

Targacept and Catalyst Biosciences Amend Definitive Merger Agreement

Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog

Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog

Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastropa

Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Pres

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blo

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog

Targacept Crumbles as Pfizer Pulls Out of Collaboration - Analyst Blog

Why I Am Still Long Targacept After The Reverse Merger Announcement

Targacept Management Increases Urgency And Aims For Q4 Strategic Action

See More TRGT News...

TRGT's Top Competitors

TRGT $2.77 (0.36%)
Current stock: TRGT
AMGN $153.26 (-1.12%)
Current stock: AMGN
GILD $115.04 (-0.84%)
Current stock: GILD
BIIB $404.28 (-0.28%)
Current stock: BIIB